DK0868435T3 - Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein - Google Patents

Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein

Info

Publication number
DK0868435T3
DK0868435T3 DK96941471T DK96941471T DK0868435T3 DK 0868435 T3 DK0868435 T3 DK 0868435T3 DK 96941471 T DK96941471 T DK 96941471T DK 96941471 T DK96941471 T DK 96941471T DK 0868435 T3 DK0868435 T3 DK 0868435T3
Authority
DK
Denmark
Prior art keywords
protein
highly efficient
streptavidin
fusion protein
tissue specific
Prior art date
Application number
DK96941471T
Other languages
English (en)
Inventor
Daniel Meruelo
Kouichi Ohno
Brandi A Levin
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of DK0868435T3 publication Critical patent/DK0868435T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
DK96941471T 1995-11-30 1996-11-26 Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein DK0868435T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/566,421 US6497881B1 (en) 1995-11-30 1995-11-30 High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
PCT/US1996/018873 WO1997019957A1 (en) 1995-11-30 1996-11-26 High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein

Publications (1)

Publication Number Publication Date
DK0868435T3 true DK0868435T3 (da) 2007-11-05

Family

ID=24262817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941471T DK0868435T3 (da) 1995-11-30 1996-11-26 Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein

Country Status (10)

Country Link
US (3) US6497881B1 (da)
EP (1) EP0868435B1 (da)
JP (1) JP4124482B2 (da)
AT (1) ATE366120T1 (da)
AU (1) AU1060397A (da)
DE (1) DE69637154T2 (da)
DK (1) DK0868435T3 (da)
ES (1) ES2289754T3 (da)
PT (1) PT868435E (da)
WO (1) WO1997019957A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
JP2002504328A (ja) 1998-02-23 2002-02-12 アーク・セラピューティックス・リミテッド ビオチン結合性レセプター分子
US6380364B1 (en) * 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
EP1718323B1 (en) * 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Binding peptidomimetics and uses of the same
US20080254551A1 (en) * 2004-12-30 2008-10-16 Achsel Tilmann Immunoprecipitaion-Based Method to Purify and Characterise Biological Macromolecular Complexes
DK2220107T3 (da) 2007-11-12 2017-02-13 Chreto Aps Polypeptid med dobbelt affinitet til oprensning
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
CN107108750A (zh) * 2014-10-28 2017-08-29 默克专利股份公司 细胞表面上非共价含Fc结构域的蛋白质展示的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
US5407653A (en) * 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein

Also Published As

Publication number Publication date
DE69637154T2 (de) 2008-03-13
JP4124482B2 (ja) 2008-07-23
JP2000502885A (ja) 2000-03-14
EP0868435A1 (en) 1998-10-07
EP0868435A4 (en) 2001-04-04
ES2289754T3 (es) 2008-02-01
EP0868435B1 (en) 2007-07-04
US20030113337A1 (en) 2003-06-19
US6497881B1 (en) 2002-12-24
WO1997019957A1 (en) 1997-06-05
AU1060397A (en) 1997-06-19
ATE366120T1 (de) 2007-07-15
DE69637154D1 (de) 2007-08-16
US20090098148A1 (en) 2009-04-16
PT868435E (pt) 2007-10-01

Similar Documents

Publication Publication Date Title
DK0868435T3 (da) Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein
PL352332A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
ATE338127T1 (de) Ribonukleaseresistente rna präparation und seine verwendung
DE69942485D1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
AU4981101A (en) Subtilisin variants
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
WO1996021007A3 (en) Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
CO4810339A1 (es) Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion
NO20013371L (no) Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner
DE69703813D1 (de) System zur expression von heterologen antigenen als fusionsproteine
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
NZ304570A (en) Neurone-restrictive silencer factor proteins, nucleic acids and antibodies thereto
DE69634077D1 (de) Haemophilus adhäsionsproteinen
ATE265533T1 (de) Saeugetierchemokine
YU69691A (sh) Postupak za pripremu stranih proteina u streptomicetama
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
ATE309370T1 (de) Retinoid-metabolisierendes protein
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
FI960427L (fi) Menetelmä prokarioottisten mikro-organismien periplasmassa esiintyvienproteiinien eristämiseksi arginiininläsnä ollessa
MX9603266A (es) Genes de timocina de mamiferos.
DE69527640D1 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52